Collegium Pharmaceutical Net Income
| COLL Stock | USD 45.79 0.51 1.13% |
As of the 14th of February 2026, Collegium Pharmaceutical shows the Mean Deviation of 1.61, risk adjusted performance of 0.0433, and Downside Deviation of 2.43. Collegium Pharmaceutical technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Collegium Pharmaceutical downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Collegium Pharmaceutical is priced correctly, providing market reflects its regular price of 45.79 per share. Given that Collegium Pharmaceutical has jensen alpha of 0.0489, we suggest you to validate Collegium Pharmaceutical's prevailing market performance to make sure the company can sustain itself at a future point.
Collegium Pharmaceutical Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 2.5882 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 79.6 M | 83.5 M | |
| Net Income From Continuing Ops | 79.6 M | 83.5 M | |
| Net Loss | -28.8 M | -30.2 M | |
| Net Income Per Share | 1.93 | 2.03 | |
| Net Income Per E B T | 0.63 | 0.66 |
Collegium | Net Income | Build AI portfolio with Collegium Stock |
Historical Net Income data for Collegium Pharmaceutical serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Collegium Pharmaceutical represents a compelling investment opportunity.
Latest Collegium Pharmaceutical's Net Income Growth Pattern
Below is the plot of the Net Income of Collegium Pharmaceutical over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Collegium Pharmaceutical financial statement analysis. It represents the amount of money remaining after all of Collegium Pharmaceutical operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Collegium Pharmaceutical's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Collegium Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 69.19 M | 10 Years Trend |
|
Net Income |
| Timeline |
Collegium Net Income Regression Statistics
| Arithmetic Mean | 757,437 | |
| Coefficient Of Variation | 7,040 | |
| Mean Deviation | 44,021,742 | |
| Median | (16,197,000) | |
| Standard Deviation | 53,325,354 | |
| Sample Variance | 2843.6T | |
| Range | 177.7M | |
| R-Value | 0.66 | |
| Mean Square Error | 1692.5T | |
| R-Squared | 0.44 | |
| Significance | 0 | |
| Slope | 7,020,507 | |
| Total Sum of Squares | 45497.5T |
Collegium Net Income History
Other Fundumenentals of Collegium Pharmaceutical
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Collegium Pharmaceutical Net Income component correlations
Collegium Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Collegium Pharmaceutical is extremely important. It helps to project a fair market value of Collegium Stock properly, considering its historical fundamentals such as Net Income. Since Collegium Pharmaceutical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Collegium Pharmaceutical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Collegium Pharmaceutical's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. Projected growth potential of Collegium fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Collegium Pharmaceutical assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 2.132 | Earnings Share 1.63 | Revenue Per Share | Quarterly Revenue Growth 0.314 | Return On Assets |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Collegium Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Collegium Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Collegium Pharmaceutical's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Collegium Pharmaceutical 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Collegium Pharmaceutical's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Collegium Pharmaceutical.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Collegium Pharmaceutical on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Collegium Pharmaceutical or generate 0.0% return on investment in Collegium Pharmaceutical over 90 days. Collegium Pharmaceutical is related to or competes with Amphastar, Dynavax Technologies, Cronos, Goodrx Holdings, Innoviva, Pacira BioSciences, and MiMedx. Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain manag... More
Collegium Pharmaceutical Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Collegium Pharmaceutical's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Collegium Pharmaceutical upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.43 | |||
| Information Ratio | 0.0139 | |||
| Maximum Drawdown | 12.24 | |||
| Value At Risk | (3.40) | |||
| Potential Upside | 3.89 |
Collegium Pharmaceutical Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Collegium Pharmaceutical's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Collegium Pharmaceutical's standard deviation. In reality, there are many statistical measures that can use Collegium Pharmaceutical historical prices to predict the future Collegium Pharmaceutical's volatility.| Risk Adjusted Performance | 0.0433 | |||
| Jensen Alpha | 0.0489 | |||
| Total Risk Alpha | (0.07) | |||
| Sortino Ratio | 0.0125 | |||
| Treynor Ratio | 0.1308 |
Collegium Pharmaceutical February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0433 | |||
| Market Risk Adjusted Performance | 0.1408 | |||
| Mean Deviation | 1.61 | |||
| Semi Deviation | 2.19 | |||
| Downside Deviation | 2.43 | |||
| Coefficient Of Variation | 2179.37 | |||
| Standard Deviation | 2.18 | |||
| Variance | 4.77 | |||
| Information Ratio | 0.0139 | |||
| Jensen Alpha | 0.0489 | |||
| Total Risk Alpha | (0.07) | |||
| Sortino Ratio | 0.0125 | |||
| Treynor Ratio | 0.1308 | |||
| Maximum Drawdown | 12.24 | |||
| Value At Risk | (3.40) | |||
| Potential Upside | 3.89 | |||
| Downside Variance | 5.89 | |||
| Semi Variance | 4.8 | |||
| Expected Short fall | (1.54) | |||
| Skewness | (0.05) | |||
| Kurtosis | 1.36 |
Collegium Pharmaceutical Backtested Returns
As of now, Collegium Stock is very steady. Collegium Pharmaceutical secures Sharpe Ratio (or Efficiency) of 0.0181, which signifies that the company had a 0.0181 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Collegium Pharmaceutical, which you can use to evaluate the volatility of the firm. Please confirm Collegium Pharmaceutical's Mean Deviation of 1.61, risk adjusted performance of 0.0433, and Downside Deviation of 2.43 to double-check if the risk estimate we provide is consistent with the expected return of 0.0379%. Collegium Pharmaceutical has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.69, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Collegium Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Collegium Pharmaceutical is expected to be smaller as well. Collegium Pharmaceutical right now shows a risk of 2.1%. Please confirm Collegium Pharmaceutical downside variance, and the relationship between the sortino ratio and accumulation distribution , to decide if Collegium Pharmaceutical will be following its price patterns.
Auto-correlation | -0.02 |
Very weak reverse predictability
Collegium Pharmaceutical has very weak reverse predictability. Overlapping area represents the amount of predictability between Collegium Pharmaceutical time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Collegium Pharmaceutical price movement. The serial correlation of -0.02 indicates that only 2.0% of current Collegium Pharmaceutical price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.02 | |
| Spearman Rank Test | -0.11 | |
| Residual Average | 0.0 | |
| Price Variance | 1.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Collegium Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Collegium Pharmaceutical reported net income of 69.19 M. This is 79.73% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is 87.88% higher than that of the company.
Collegium Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Collegium Pharmaceutical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Collegium Pharmaceutical could also be used in its relative valuation, which is a method of valuing Collegium Pharmaceutical by comparing valuation metrics of similar companies.Collegium Pharmaceutical is currently under evaluation in net income category among its peers.
Collegium Pharmaceutical Current Valuation Drivers
We derive many important indicators used in calculating different scores of Collegium Pharmaceutical from analyzing Collegium Pharmaceutical's financial statements. These drivers represent accounts that assess Collegium Pharmaceutical's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Collegium Pharmaceutical's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 689.2M | 652.6M | 1.0B | 924.6M | 832.2M | 454.3M | |
| Enterprise Value | 781.7M | 724.9M | 1.5B | 1.7B | 1.5B | 1.6B |
Collegium Pharmaceutical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Collegium Pharmaceutical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Collegium Pharmaceutical's managers, analysts, and investors.Environmental | Governance | Social |
Collegium Pharmaceutical Institutional Holders
Institutional Holdings refers to the ownership stake in Collegium Pharmaceutical that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Collegium Pharmaceutical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Collegium Pharmaceutical's value.| Shares | Massachusetts Financial Services Company | 2025-06-30 | 799.2 K | Geode Capital Management, Llc | 2025-06-30 | 780.2 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 613.8 K | Emerald Mutual Fund Advisers Trust | 2025-06-30 | 550.6 K | Bank Of America Corp | 2025-06-30 | 514.8 K | Victory Capital Management Inc. | 2025-06-30 | 508.8 K | Hhg Plc | 2025-06-30 | 469.5 K | Charles Schwab Investment Management Inc | 2025-06-30 | 386.1 K | Northern Trust Corp | 2025-06-30 | 380.8 K | Blackrock Inc | 2025-06-30 | 5.3 M | Rubric Capital Management Lp | 2025-06-30 | 3.2 M |
Collegium Fundamentals
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.0675 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.32 % | ||||
| Current Valuation | 1.96 B | ||||
| Shares Outstanding | 31.61 M | ||||
| Shares Owned By Insiders | 1.58 % | ||||
| Shares Owned By Institutions | 98.42 % | ||||
| Number Of Shares Shorted | 4.79 M | ||||
| Price To Earning | 28.80 X | ||||
| Price To Book | 5.21 X | ||||
| Price To Sales | 1.89 X | ||||
| Revenue | 631.45 M | ||||
| Gross Profit | 667.51 M | ||||
| EBITDA | 341.7 M | ||||
| Net Income | 69.19 M | ||||
| Cash And Equivalents | 122.72 M | ||||
| Cash Per Share | 3.60 X | ||||
| Total Debt | 859.3 M | ||||
| Debt To Equity | 3.82 % | ||||
| Current Ratio | 0.99 X | ||||
| Book Value Per Share | 8.70 X | ||||
| Cash Flow From Operations | 204.98 M | ||||
| Short Ratio | 9.39 X | ||||
| Earnings Per Share | 1.63 X | ||||
| Target Price | 53.67 | ||||
| Number Of Employees | 357 | ||||
| Beta | 0.65 | ||||
| Market Capitalization | 1.43 B | ||||
| Total Asset | 1.66 B | ||||
| Retained Earnings | (164 M) | ||||
| Working Capital | (27.25 M) | ||||
| Current Asset | 96.88 M | ||||
| Current Liabilities | 8.43 M | ||||
| Net Asset | 1.66 B |
About Collegium Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Collegium Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Collegium Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Collegium Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. Projected growth potential of Collegium fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Collegium Pharmaceutical assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 2.132 | Earnings Share 1.63 | Revenue Per Share | Quarterly Revenue Growth 0.314 | Return On Assets |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Collegium Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Collegium Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Collegium Pharmaceutical's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.